CA-CREDENCE-MEDSYSTEMS
26.1.2021 07:09:06 CET | Business Wire | Press release
Credence MedSystems announced today that Novartis has made a strategic investment in the Company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems, with an initial focus on the Credence Companion® Safety Syringe System. With the investment in Credence, Novartis seeks to support its patients, caregivers, and healthcare professionals by enhancing the safety and user experience during administration of Novartis injectable medications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005138/en/
The Credence Companion allows pharmaceutical manufacturers to provide critical usability and safety features to their end-users. At the completion of the injection, the user receives end-of-dose cues indicating that the full dose has been delivered, and the needle automatically retracts into the syringe barrel. The enhanced usability can contribute to improved adherence, while the passive needle retraction helps protect users from accidental needlesticks and prevents reuse of the syringe.
Credence Companion technology integrates with the syringe before the medication is filled. To facilitate implementation for pharmaceutical manufacturers and offer this technology for a variety of applications and therapeutic fields, a fully integrated solution that is compatible with various syringe barrels is a prerequisite. The integrated approach to safety, where no additional devices need to be assembled after syringe filling, brings operational efficiencies to drug manufacturers. In support of this more efficient approach to the market, a collaboration between Credence and SCHOTT AG for the application of Credence Companion technology with SCHOTT’s pre-fillable glass and polymer syringe systems has recently been announced.
Jeff Tillack and John Merhige, Credence’s COO and CCO, jointly stated, “We are excited to welcome Novartis as a strategic investor. This represents an important validation of Credence technology in the market and helps support our continued growth. We look forward to working together with Novartis to improve the user experience and contribute to better patient outcomes.”
About Credence MedSystems, Inc.
Credence MedSystems is an innovator of drug delivery systems that solve unmet market needs for the pharmaceutical industry. Credence’s philosophy of Innovation Without Change allows pharma manufacturers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion® family of syringe systems includes proprietary needle retraction technology, syringe reuse prevention and other critical safety and usability features. The Dual Chamber Reconstitution platform offers single-step mixing and injection for medicines that require reconstitution at the time of delivery. The Credence Connect™ brings digital connectivity to any prefilled syringe. Metered dose systems and other novel devices address the needs of specific therapeutic markets such as ocular therapies and cosmetic applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 15:09:00 CEST | Press release
Agent Hub, part of Earnix AIOS, brings more than 25, insurance-specific agents and apps into Earnix’s governed pricing, underwriting, and customer decision solutions- improving workflows and business performance Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and i
Medisca Launches Global Peptide Division17.9.2026 15:07:00 CEST | Press release
New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation. For Medisca, the opportunity is familiar. More than 35 years ago, the company was founded t
Elliptic Launches Its Decode Agent to Answer On-Chain Risk Questions and Shows Its Work17.9.2026 15:00:00 CEST | Press release
Hours of tracing, answered in seconds, with the evidence attached Elliptic, the global leader in on-chain risk, today launched Decode, an AI agent built on Elliptic’s intelligence platform. The Decode agent answers natural-language questions about cryptoasset addresses and their exposure in seconds, and returns the evidence behind every answer. Compliance and investigations teams need answers to questions nobody planned for. Getting them out of the data is now a specialist skill, so the questions wait for someone who has it, or go unasked. Meanwhile illicit actors move at machine speed, and agents are starting to sit on both sides of a payment. General-purpose AI assistants can produce an answer. They cannot show where it came from. A fluent response with nothing behind it cannot be put in front of a second-line reviewer, an auditor, or a regulator. “The market is full of AI that asks to be trusted. That is not good enough when someone asks how you reached a decision,” said Jackson Hul
AMRA Medical Earns TIME’s Highest “Outstanding” Rating in World’s Top HealthTech Companies 202617.9.2026 14:51:00 CEST | Press release
AMRA is the only European company in the Diagnostics segment to receive the highest designation, recognizing its work in MRI-based muscle and fat analysis. The 2026 result builds on AMRA’s inclusion in the inaugural ranking in 2025, when the company received a “Very High” designation. Its advancement to the top category reflects continued progress in scientific excellence and technological innovation, as well as the expanding application of MRI-based biomarkers across research, drug development, and clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917956850/en/ “Being recognized by TIME and Statista for the second consecutive year and receiving the highest ‘Outstanding’ designation is a meaningful recognition of AMRA’s continued progress,” said Olof Dahlqvist Leinhard, CEO of AMRA Medical. “It reflects the dedication of our team and the strong scientific foundation behind our work. Our mission is to advance t
INNIO Secures 450 MW Order to Power Next-Generation Data Centers17.9.2026 14:30:00 CEST | Press release
U.S. based energy company orders Jenbacher J624 containerized engines to support deployment of fast-track, behind-the-meter power solutions for large-scale data centers 450 MW firm order booked in Q3 2026 INNIO N.V. (Nasdaq: INIO) today announced it has secured an order from a U.S. energy company for 450 megawatts (MW) of power infrastructure. INNIO's Jenbacher J624 containerized gas engines will support the deployment of prime power solutions for large-scale data center projects in North America. The order reflects continued demand for the company's high-efficiency gas engine technology as data center developers seek off-grid alternatives to constrained grid infrastructure. This is the first order by the customer of this scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917646026/en/ INNIO secures 450 MW order to power next-generation data centers The engines are expected to be delivered by 2028. The firm order was b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom